13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001389933
Total reported value
$524.4M
$524.4M
75 檔
29.8%
During the Q3 2025 filing period, DAFNA Capital Management LLC (CIK: 0001389933) submitted its Form 13F report to the U.S. SEC, disclosing a tracked public equity portfolio valued at $524.4M across 75 reported positions.
In Q3 2025, DAFNA Capital Management LLC adopted a defensive or profit-taking posture, trimming 26 positions and completely liquidating 16 holdings to manage risk exposure.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | STXS | Stereotaxis Inc | Stock-Other | 10.51% | -1.24% | — | |
| 2 | XBI | Ss Spdr S&p Biotech ETF | ETF-Tech | 9.94% | -3.32% | -3.37% | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 7.58% | +7.24% | -2.95% | |
| 4 | CYTK | Cytokinetics Inc | Stock-Healthcare | 5.36% | -0.47% | -0.79% | |
| 5 | ATRC | Atricure Inc | Stock-Other | 5.16% | -0.69% | — | |
| 6 | ✓ | Merus N V | Stock-Other | 5.13% | — | -44.72% | |
| 7 | IBB | Ishares Biotechnology ETF | ETF-Tech | 3.66% | -0.85% | — | |
| 8 | IDYA | Ideaya Biosciences Inc | Stock-Other | 3.63% | -0.08% | -12.79% | |
| 9 | AXGN | Axogen Inc | Stock-Other | 3.27% | -0.04% | +0.07% | |
| 10 | XENE | Xenon Pharmaceuticals Inc | Stock-Other | 2.86% | -0.43% | — | |
| 11 | NBIX | Neurocrine Biosciences Inc | Stock-Healthcare | 2.45% | -0.26% | — | |
| 12 | RCUS | Arcus Biosciences Inc | Stock-Other | 2.11% | +0.42% | — | |
| 13 | SNDX | Syndax Pharmaceuticals Inc | Stock-Other | 1.90% | +0.24% | -7.89% | |
| 14 | DAWNGBX | Day One Biopharmaceuticals I | Stock-Other | 1.74% | -4.77% | EXIT | |
| 15 | ASND | Ascendis Pharma A/S | Stock-Other | 1.63% | -1.21% | EXIT | |
| 16 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | Bond | 1.34% | -1.35% | EXIT | |
| 17 | 4XC1 | Kalvista Pharmaceuticals Inc | Stock-Other | 1.27% | -1.22% | EXIT | |
| 18 | BCAX | Bicara Therapeutics Inc | Stock-Other | 1.24% | -0.30% | — | |
| 19 | INGN | Inogen Inc | Stock-Other | 1.22% | -0.15% | — | |
| 20 | CMPS | Compass Pathways PLC | Stock-Other | 1.15% | +2.39% | — | |
| 21 | LKFT | Lakefront Biotherapeutic-adr | Stock-Other | 1.11% | -0.15% | — | |
| 22 | DXCM | Dexcom Inc | Stock-Healthcare | 1.09% | -0.12% | — | |
| 23 | TNDM | Tandem Diabetes Care Inc | Stock-Other | 1.07% | -0.53% | +20.73% | |
| 24 | KURA | Kura Oncology Inc | Stock-Other | 1.01% | -0.19% | — | |
| 25 | ALKS | Alkermes plc | Stock-Healthcare | 1.00% | -0.11% | +29.88% | |
| 26 | STOK | Stoke Therapeutics Inc | Stock-Other | 0.99% | -0.15% | -66.18% | |
| 27 | SLNOEUR | Soleno Therapeutics Inc | Stock-Other | 0.89% | — | — | |
| 28 | BHVN | Biohaven Ltd. | Stock-Other | 0.87% | -1.24% | — | |
| 29 | EWTX | Edgewise Therapeutics Inc | Stock-Other | 0.86% | +0.96% | -10.25% | |
| 30 | ✓ | Proqr Therapeutics N.v. | Stock-Other | 0.82% | -0.04% | — | |
| 31 | LRMR | Larimar Therapeutics Inc | Stock-Other | 0.82% | -0.91% | +176.70% | |
| 32 | CMPX | Compass Therapeutics Inc | Stock-Other | 0.82% | — | +79.75% | |
| 33 | MLYS | Mineralys Therapeutics Inc | Stock-Other | 0.78% | -0.01% | -77.53% | |
| 34 | NKTR | Nektar Therapeutics | Stock-Other | 0.77% | +1.54% | +449.98% | |
| 35 | IMVT | Immunovant Inc | Stock-Other | 0.76% | +0.25% | — | |
| 36 | KRRO | Korro Bio Inc | Stock-Other | 0.72% | — | +5.40% | |
| 37 | AQST | Aquestive Therapeutics Inc | Stock-Other | 0.71% | +0.16% | +260.98% | |
| 38 | DNLI | Denali Therapeutics Inc | Stock-Other | 0.60% | +2.23% | — | |
| 39 | LXEO | Lexeo Therapeutics Inc | Stock-Other | 0.59% | -0.16% | -5.29% | |
| 40 | ALEC | Alector Inc | Stock-Other | 0.58% | -0.09% | -12.55% | |
| 41 | CATBUSD | Astria Therapeutics Inc | Stock-Other | 0.58% | — | -1.54% | |
| 42 | RAPP | Rapport Therapeutics Inc | Stock-Other | 0.55% | +0.07% | — | |
| 43 | TELA | Tela Bio Inc | Stock-Other | 0.53% | +0.01% | — | |
| 44 | PODD | Insulet CORP | Stock-Healthcare | 0.52% | +1.28% | -30.61% | |
| 45 | ✓ | Mediwound LTD | Stock-Other | 0.51% | -0.09% | +76.20% | |
| 46 | ARAY | Accuray Inc | Stock-Other | 0.50% | -0.07% | — | |
| 47 | ✓ | Immatics NV | Stock-Other | 0.49% | -0.28% | -4.08% | |
| 48 | ALLO | Allogene Therapeutics Inc | Stock-Other | 0.42% | +0.03% | — | |
| 49 | VKTX | Viking Therapeutics Inc | Stock-Healthcare | 0.42% | — | — | |
| 50 | BCRX | Biocryst Pharmaceuticals Inc | Stock-Other | 0.41% | -0.17% | — |
| # | Ticker | Issuer | Weight Change | Shares Change | Action |
|---|---|---|---|---|---|
| 1 | STXS | Stereotaxis Inc | +3.7% | — | Unchanged |
| 2 | RVMD | Revolution Medicines Inc | +1% | -2.95% | Add |
| 3 | IDYA | Ideaya Biosciences Inc | +0.9% | -12.79% | Trim |
| 4 | CYTK | Cytokinetics Inc | +0.8% | -0.79% | Trim |
| 5 | RCUS | Arcus Biosciences Inc | +0.7% | — | Add |
| 6 | XBI | Ss Spdr S&p Biotech ETF | +0.6% | -3.37% | Trim |
| 7 | LRMR | Larimar Therapeutics Inc | +0.6% | +176.70% | Add |
| 8 | AQST | Aquestive Therapeutics Inc | +0.6% | +260.98% | Add |
| 9 | CMPS | Compass Pathways PLC | +0.6% | — | Add |
| 10 | KRRO | Korro Bio Inc | +0.5% | +5.40% | Add |
| 11 | BCAX | Bicara Therapeutics Inc | +0.5% | — | Add |
| 12 | INGN | Inogen Inc | +0.3% | — | Add |
| 13 | XENE | Xenon Pharmaceuticals Inc | +0.3% | — | Add |
| 14 | ALEC | Alector Inc | +0.3% | -12.55% | Trim |
| 15 | ✓ | Proqr Therapeutics N.v. | +0.2% | — | Unchanged |
| 16 | ✓ | Mediwound LTD | +0.2% | +76.20% | Add |
| 17 | BDTX | Black Diamond Therapeutics I | +0.2% | -34.80% | Add |
| 18 | LXEO | Lexeo Therapeutics Inc | +0.2% | -5.29% | Trim |
| 19 | NBIX | Neurocrine Biosciences Inc | +0.2% | — | Trim |
| 20 | LKFT | Lakefront Biotherapeutic-adr | +0.2% | — | Unchanged |
| 21 | ✓ | Immatics NV | +0.2% | -4.08% | Trim |
| 22 | STOK | Stoke Therapeutics Inc | +0.2% | -66.18% | Trim |
| 23 | KURA | Kura Oncology Inc | +0.1% | — | Unchanged |
| 24 | ALKS | Alkermes plc | +0.1% | +29.88% | Add |
| 25 | GPCR | Structure Therapeutics Inc | +0.1% | — | Unchanged |
| 26 | DNLI | Denali Therapeutics Inc | +0.1% | — | Add |
| 27 | DAWNGBX | Day One Biopharmaceuticals I | +0.1% | +13.65% | Add |
| 28 | CATBUSD | Astria Therapeutics Inc | +0.1% | -1.54% | Add |
| 29 | ERAS | Erasca Inc | +0.1% | — | Add |
| 30 | TELA | Tela Bio Inc | 0% | — | Unchanged |
| 31 | ✓ | Adc Therapeutics SA | 0% | — | Trim |
| 32 | SPRY | Ars Pharmaceuticals Inc | 0% | — | Add |
| 33 | STRO | Sutro Biopharma, Inc. | 0% | — | Unchanged |
| 34 | SNDX | Syndax Pharmaceuticals Inc | — | -7.89% | Trim |
| 35 | ASND 2.25 04-01-28Bond | Ascendis Pharma A/s | — | — | Unchanged |
| 36 | ✓ | 0% | — | Unchanged | |
| 37 | ✓ | Compugen LTD | 0% | — | Unchanged |
| 38 | VKTX | Viking Therapeutics Inc | 0% | — | Unchanged |
| 39 | IPSC | Century Therapeutics Inc | 0% | — | Unchanged |
| 40 | APRE | Aprea Therapeutics Inc | 0% | — | Unchanged |
| 41 | NGNE | Neurogene Inc | 0% | -40.55% | Trim |
| 42 | ✓ | Polypid LTD | -0.1% | — | Trim |
| 43 | IBB | Ishares Biotechnology ETF | -0.1% | — | Unchanged |
| 44 | IMVT | Immunovant Inc | -0.1% | — | Add |
| 45 | KROS | Keros Therapeutics Inc | -0.1% | -38.06% | Trim |
| 46 | BCYC | Bicycle Therapeutics Plc-adr | -0.1% | — | Trim |
| 47 | ORIC | Oric Pharmaceuticals Inc | -0.1% | -22.62% | Trim |
| 48 | BNTX | Biontech Se-adr | -0.1% | — | Trim |
| 49 | ARAY | Accuray Inc | -0.1% | — | Unchanged |
| 50 | ALLO | Allogene Therapeutics Inc | -0.2% | — | Unchanged |
According to official SEC Form 13F filings, DAFNA Capital Management LLC reported a total U.S. public equity portfolio value of $524.4M across 75 disclosed positions in Q3 2025.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In terms of portfolio concentration, the top 5 core holdings (including STXS, XBI, RVMD) accounted for 29.8% of total reported equity market value during Q3 2025.
Top New Position Initiated
SLNOEUR
市值: $3.6M
Top Position Liquidated / Trimmed
2655787D
前期市值: $13.5M
During Q3 2025, DAFNA Capital Management LLC's top holdings by market value included STXS (10.5%)、XBI (9.9%)、RVMD (7.6%). The largest single position, STXS, represented 10.5% of total portfolio value.
In Q3 2025, DAFNA Capital Management LLC made 72 total portfolio adjustments, initiating 8 new buys, adding to 22 positions, trimming 26 holdings, and fully liquidating 16 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.